Stock comparison
Guardian Pharmacy Services
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GRDN
Guardian Pharmacy Services
Market cap
$2.44B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GRDN | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 72B | RMD |
| Benjamin Graham | 62D | 75B | RMD |
| Philip Fisher | 57C | 75B | RMD |
| Peter Lynch | 60C | 58C | GRDN |
| Joel Greenblatt | 61C | 47D | GRDN |
| Charlie Munger | 47D | 69B | RMD |
| Terry Smith | 52C | 73B | RMD |
Side-by-side metrics
| Metric | GRDN | RMD |
|---|---|---|
| Market cap | $2.44B | $30.18B |
| P/E (TTM) | 42.7x | 19.6x |
| EV/EBIT | 30.8x | 17.1x |
| ROIC (TTM) | 20.71% | 19.63% |
| Gross margin | 20.93% | 61.69% |
| Net margin | 3.64% | 27.44% |
| Revenue CAGR 5y | 16.29% | 12.64% |
| EPS CAGR 5y | 30.79% | 30.73% |
| Debt / Equity | 0.2x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GRDN leads on
- Revenue CAGR 5y16.29%vs 12.64%+22%
- ROIC (TTM)20.71%vs 19.63%+5%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $2.44B+92%
- Net margin27.44%vs 3.64%+87%
- Gross margin61.69%vs 20.93%+66%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.